Aspirin Use and Misuse for the Primary Prevention of Cardiovascular Diseases

Research output: Contribution to journalArticlepeer-review

Abstract

Introduction: Daily aspirin use for primary cardiovascular disease prevention is common among adults. Numerous clinical trials observe reduced cardiovascular disease with regular low-dose aspirin. The U.S. Preventive Services Task Force in 2016 published guidelines for aspirin use, but controversy exists about the side effects, and overuse or underuse may be common despite the guidelines. Using the Task Force recommendations, this paper describes the prevalence of appropriate aspirin use and physician advice in a population sample. Methods: A random sample of men and women (aged 50–69 years) living in the Upper Midwest in 2017–2018 were surveyed, collecting demographic data, health history, and aspirin use. Appropriate primary prevention with aspirin was defined as having ≥10% cardiovascular disease risk (hypertension, hyperlipidemia, diabetes, smoking) with daily or every other day aspirin use. Those with prevalent cardiovascular disease were labeled as secondary prevention. Results: A total of 1,352 adults were surveyed (697 women, 655 men). The criteria for secondary prevention were fulfilled in 188 participants, and these were eliminated from the analysis. In the remaining group, aspirin was indicated in 32.9% (383 of 1,164). Among those, 46.0% (176 of 383) were appropriate users, and 54.0% (207 of 383) were nonusers despite indications. Overuse, where aspirin is not indicated, was common at 26.9% (210 of 781). Discussion with a physician, although reported in 29% of subjects, was associated with some improvement in the appropriate use but also with overuse and underuse. Conclusions: Aspirin use for primary cardiovascular disease prevention is common. However, many adults are medicating without indication (overuse) or are not using aspirin despite guidelines (underuse).

Original languageEnglish (US)
Pages (from-to)513-519
Number of pages7
JournalAmerican journal of preventive medicine
Volume60
Issue number4
DOIs
StatePublished - Apr 2021

Bibliographical note

Funding Information:
This research was supported by the National Heart Lung and Blood Institute of the NIH (R01HL126041). No financial disclosures were reported by the authors for this paper.

Funding Information:
This research was supported by the National Heart Lung and Blood Institute of the NIH ( R01HL126041 ).

Publisher Copyright:
© 2021 American Journal of Preventive Medicine

Fingerprint Dive into the research topics of 'Aspirin Use and Misuse for the Primary Prevention of Cardiovascular Diseases'. Together they form a unique fingerprint.

Cite this